Senate Democrats have asked Donald Trump’s nominee for health secretary how he would lower nationwide drug prices when as a pharmaceutical industry executive he presided over some drug costs doubling.
Alex Azar, set to become director of the Department of Health and Human Services (HHS), appeared before the Senate at a confirmation hearing on 10 January. The ex senior executive at pharmaceutical company Eli Lilly said that addressing skyrocketing US drug prices would be a top priority for him.
But Democrats produced charts that showed some of Eli Lilly’s drug prices more than doubled on Azar’s watch.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.